PFE
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Financial indicators Supports a bullish reading. Current ratio 1.16 · operating margin 25%
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 114 863 titres (~2 960 109,90 $ US)
- Insiders
- BOURLA ALBERTBLAYLOCK RONALD EBuckley Mortimer J
- Total bought
-
$2,960,110
Avg buy (VWAP, 90d window) $25.77 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) $25.40 vs last close —
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-12 | BOURLA ALBERT | Buy | 38,000 | $26.34 | $1,000,920 | Form 4 |
| 2026-08-05 | DAMICO JENNIFER B. | Sell | 3,278 | $25.40 | $83,261 | Form 4 |
| 2026-08-05 | BLAYLOCK RONALD E | Buy | 39,231 | $25.46 | $998,821 | Form 4 |
| 2026-08-05 | Buckley Mortimer J | Buy | 37,632 | $25.52 | $960,369 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-06
A strong insider cluster buy (~$3M, including a $1M CEO purchase post-Q2) combined with a positive EMA validation for the Lyme vaccine pipeline provides a meaningful event-driven signal (catalyst score 75, confidence…
The first sentence of the analysis written for PFE on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 70.3% | 65.8% | 50.9% | 61.9% | 57.7% | |
| Ebit Margin | 16.3% | 17.5% | 5.5% | 35.8% | 31.5% | |
| Ebitda Margin | 24.1% | 28.5% | 16.0% | 40.9% | 37.9% | |
| Operating Profit Margin | 24.7% | 25.9% | 8.9% | 37.4% | 25.6% | |
| Pretax Profit Margin | 12.0% | 12.6% | 1.8% | 34.6% | 29.9% | |
| Continuous Operations Profit Margin | 12.4% | 12.7% | 3.6% | 31.3% | 27.6% | |
| Net Profit Margin | 12.4% | 12.6% | 3.6% | 31.3% | 27.2% | |
| Bottom Line Profit Margin | 12.4% | 12.6% | 3.6% | 31.3% | 27.2% | |
| Current Ratio | 1.160 | 1.171 | 0.907 | 1.216 | 1.399 | |
| Quick Ratio | 0.872 | 0.919 | 0.693 | 1.003 | 1.187 | |
| Solvency Ratio | 0.104 | 0.120 | 0.061 | 0.360 | 0.263 | |
| Cash Ratio | 0.031 | 0.024 | 0.060 | 0.010 | 0.046 | |
| Price To Earnings Ratio | 18.309 | 18.683 | 76.671 | 9.162 | 14.935 | |
| Price To Earnings Growth Ratio | -4.333 | 0.067 | -0.822 | 0.221 | 0.107 | |
| Forward Price To Earnings Growth Ratio | -4.333 | 0.067 | -0.822 | 0.221 | 0.107 | |
| Price To Earnings Diluted Ratio | 18.309 | 18.816 | 77.559 | 9.366 | 15.220 | |
| Price To Earnings Diluted Growth Ratio | -5.163 | 0.067 | -0.832 | 0.228 | 0.110 | |
| Price To Book Ratio | 1.636 | 1.704 | 1.825 | 3.004 | 4.284 | |
| Price To Sales Ratio | 2.261 | 2.362 | 2.728 | 2.864 | 4.069 | |
| Price To Free Cash Flow Ratio | 15.591 | 15.279 | 33.896 | 11.039 | 11.073 | |
| Price To Operating Cash Flow Ratio | 12.089 | 11.791 | 18.674 | 9.818 | 10.152 | |
| Debt To Assets Ratio | 0.324 | 0.314 | 0.313 | 0.177 | 0.204 | |
| Debt To Equity Ratio | 0.780 | 0.760 | 0.796 | 0.364 | 0.479 | |
| Debt To Capital Ratio | 0.438 | 0.432 | 0.443 | 0.267 | 0.324 | |
| Long Term Debt To Capital Ratio | 0.416 | 0.394 | 0.405 | 0.250 | 0.310 | |
| Financial Leverage Ratio | 2.407 | 2.419 | 2.545 | 2.062 | 2.351 | |
| Working Capital Turnover Ratio | 9.427 | 43.850 | 25.559 | 7.675 | 6.213 | |
| Operating Cash Flow Ratio | 0.316 | 0.296 | 0.182 | 0.695 | 0.764 | |
| Operating Cash Flow Sales Ratio | 0.187 | 0.200 | 0.146 | 0.292 | 0.401 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.775 | 0.772 | 0.551 | 0.889 | 0.917 | |
| Debt Service Coverage Ratio | 2.496 | 1.809 | 0.850 | 9.037 | 8.194 | |
| Interest Coverage Ratio | 5.779 | 5.333 | 2.396 | 30.330 | 16.106 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.360 | 1.835 | 0.841 | 9.975 | 14.538 | |
| Operating Cash Flow Coverage Ratio | 0.174 | 0.190 | 0.123 | 0.840 | 0.881 | |
| Capital Expenditure Coverage Ratio | 4.452 | 4.381 | 2.227 | 9.044 | 12.018 | |
| Dividend Paid And Capex Coverage Ratio | 0.944 | 1.026 | 0.661 | 2.395 | 2.848 | |
| Dividend Payout Ratio | 1.258 | 1.186 | 4.335 | 0.286 | 0.394 | |
| Enterprise Value Multiple | 13.764 | 11.928 | 24.114 | 7.843 | 11.879 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 70.3% | ▲4.6% | ▲9.0% |
| Ebit Margin | 16.3% | ▼-1.2% | ▼-5.0% |
| Ebitda Margin | 24.1% | ▼-4.4% | ▼-5.4% |
| Operating Profit Margin | 24.7% | ▼-1.2% | ▲0.2% |
| Pretax Profit Margin | 12.0% | ▼-0.6% | ▼-6.2% |
| Continuous Operations Profit Margin | 12.4% | ▼-0.2% | ▼-5.1% |
| Net Profit Margin | 12.4% | ▼-0.2% | ▼-5.0% |
| Bottom Line Profit Margin | 12.4% | ▼-0.2% | ▼-5.0% |
| Current Ratio | 1.160 | ▼-0.011 | ▼-0.011 |
| Quick Ratio | 0.872 | ▼-0.047 | ▼-0.063 |
| Solvency Ratio | 0.104 | ▼-0.016 | ▼-0.077 |
| Cash Ratio | 0.031 | ▲0.007 | ▼-0.003 |
| Price To Earnings Ratio | 18.309 | ▼-0.374 | ▼-9.243 |
| Price To Earnings Growth Ratio | -4.333 | ▼-4.400 | ▼-3.381 |
| Forward Price To Earnings Growth Ratio | -4.333 | ▼-4.400 | ▼-3.381 |
| Price To Earnings Diluted Ratio | 18.309 | ▼-0.507 | ▼-9.545 |
| Price To Earnings Diluted Growth Ratio | -5.163 | ▼-5.230 | ▼-4.045 |
| Price To Book Ratio | 1.636 | ▼-0.067 | ▼-0.854 |
| Price To Sales Ratio | 2.261 | ▼-0.101 | ▼-0.596 |
| Price To Free Cash Flow Ratio | 15.591 | ▲0.312 | ▼-1.785 |
| Price To Operating Cash Flow Ratio | 12.089 | ▲0.298 | ▼-0.416 |
| Debt To Assets Ratio | 0.324 | ▲0.010 | ▲0.058 |
| Debt To Equity Ratio | 0.780 | ▲0.020 | ▲0.144 |
| Debt To Capital Ratio | 0.438 | ▲0.006 | ▲0.057 |
| Long Term Debt To Capital Ratio | 0.416 | ▲0.022 | ▲0.061 |
| Financial Leverage Ratio | 2.407 | ▼-0.012 | ▲0.051 |
| Working Capital Turnover Ratio | 9.427 | ▼-34.424 | ▼-9.118 |
| Operating Cash Flow Ratio | 0.317 | ▲0.020 | ▼-0.134 |
| Operating Cash Flow Sales Ratio | 0.187 | ▼-0.013 | ▼-0.058 |
| Free Cash Flow Operating Cash Flow Ratio | 0.775 | ▲0.004 | ▼-0.005 |
| Debt Service Coverage Ratio | 2.496 | ▲0.687 | ▼-1.981 |
| Interest Coverage Ratio | 5.779 | ▲0.447 | ▼-6.209 |
| Short Term Operating Cash Flow Coverage Ratio | 3.360 | ▲1.525 | ▼-2.750 |
| Operating Cash Flow Coverage Ratio | 0.174 | ▼-0.017 | ▼-0.268 |
| Capital Expenditure Coverage Ratio | 4.452 | ▲0.071 | ▼-1.972 |
| Dividend Paid And Capex Coverage Ratio | 0.944 | ▼-0.082 | ▼-0.631 |
| Dividend Payout Ratio | 1.258 | ▲0.071 | ▼-0.234 |
| Enterprise Value Multiple | 13.764 | ▲1.836 | ▼-0.142 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $141.50B | $150.27B | $162.46B | $287.35B | $330.74B | |
| Enterprise value | $207.77B | $216.22B | $230.45B | $321.80B | $365.79B | |
| EV / Sales | 3.32x | 3.40x | 3.87x | 3.21x | 4.50x | |
| EV / Op. cash flow | 17.75x | 16.97x | 26.49x | 10.99x | 11.23x | |
| EV / Free cash flow | 22.89x | 21.98x | 48.08x | 12.36x | 12.25x | |
| EV / EBITDA | 13.76x | 11.93x | 24.11x | 7.84x | 11.88x | |
| Net debt / EBITDA | 4.39x | 3.64x | 7.11x | 0.84x | 1.14x | |
| Current ratio | 1.16x | 1.17x | 0.91x | 1.22x | 1.40x | |
| Income quality | 1.51x | 1.58x | 4.01x | 0.93x | 1.45x | |
| Graham number | $22 | $22 | $12 | $46 | $35 | |
| Graham net-net | -$16 | -$16 | -$19 | -$11 | -$10 | |
| Tax burden | 103.3% | 100.0% | 201.6% | 90.3% | 91.1% | |
| Interest burden | 73.8% | 72.2% | 32.4% | 96.6% | 95.0% | |
| Working capital | $5.91B | $7.36B | -$4.46B | $9.12B | $17.02B | |
| Invested capital | $152.44B | $149.69B | $147.16B | $120.14B | $106.26B | |
| Return on assets | 3.7% | 3.8% | 0.9% | 15.9% | 12.2% | |
| Operating ROA | 7.3% | 7.5% | 2.5% | 19.8% | 12.4% | |
| Return on tangible assets | 9.3% | 9.0% | 2.3% | 30.6% | 20.7% | |
| Return on equity | 9.0% | 9.1% | 2.4% | 32.8% | 28.7% | |
| Return on invested capital | 8.8% | 9.3% | 2.8% | 21.5% | 13.6% | |
| Return on capital employed | 9.0% | 9.7% | 3.0% | 24.2% | 15.0% | |
| Earnings yield | 5.5% | 5.3% | 1.3% | 10.9% | 6.7% | |
| Free cash flow yield | 6.4% | 6.5% | 3.0% | 9.1% | 9.0% | |
| Capex / Op. cash flow | 22.5% | 22.8% | 44.9% | 11.1% | 8.3% | |
| Capex / Depreciation | 39.9% | 41.5% | 62.1% | 63.9% | 52.2% | |
| Capex / Sales | 4.2% | 4.6% | 6.6% | 3.2% | 3.3% | |
| SG&A / Sales | 21.3% | 23.2% | 24.3% | 13.1% | 15.1% | |
| R&D / Sales | 19.1% | 16.9% | 17.8% | 11.4% | 17.0% | |
| Stock comp / Sales | 0.0% | 1.4% | 0.9% | 0.9% | 1.5% | |
| Intangibles / Total assets | 60.0% | 58.1% | 58.6% | 48.0% | 41.0% | |
| Days sales outstanding | 92d | 85d | 95d | 53d | 71d | |
| Days payables outstanding | 103d | 94d | 84d | 65d | 59d | |
| Operating cycle | 302d | 267d | 223d | 139d | 167d | |
| Cash conversion cycle | 199d | 172d | 139d | 74d | 108d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-5.8%EV / Sales ▼-2.3%EV / EBITDA ▲+15.4%EV / Op. cash flow ▲+0.785Earnings yield ▲+0.002Graham number ▼-0.637
Profitability
Return on equity ▼-0.001Return on assets -0.000Return on invested capital ▼-0.004Return on capital employed ▼-0.007Operating ROA ▼-0.002Income quality ▼-0.072Tax burden ▲+0.034
Efficiency
Days sales outstanding ▲+7.626Days payables outstanding ▲+8.626Operating cycle ▲+35.252Cash conversion cycle ▲+26.626Capex / Sales ▼-0.004R&D / Sales ▲+0.023
Balance-sheet strength
Current ratio ▼-0.011Net debt / EBITDA ▲+0.752Working capital ▼-1449000000.000Invested capital ▲+2744000000.000Intangibles / Total assets ▲+0.020
Change over 5 years
Valuation
Market cap ▼-57.2%EV / Sales ▼-26.2%EV / EBITDA ▲+15.9%EV / Op. cash flow ▲+6.523Earnings yield ▼-0.012Graham number ▼-13.382
Profitability
Return on equity ▼-0.197Return on assets ▼-0.085Return on invested capital ▼-0.048Return on capital employed ▼-0.060Operating ROA ▼-0.051Income quality ▲+0.060Tax burden ▲+0.122
Efficiency
Days sales outstanding ▲+21.696Days payables outstanding ▲+43.859Operating cycle ▲+135.077Cash conversion cycle ▲+91.218Capex / Sales ▲+0.009R&D / Sales ▲+0.021
Balance-sheet strength
Current ratio ▼-0.239Net debt / EBITDA ▲+3.252Working capital ▼-11108000000.000Invested capital ▲+46181000000.000Intangibles / Total assets ▲+0.191
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-02-10 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2025-12-31 | James French Hill | Sale (Full) | $100,001 - $250,000 |
| 2025-12-19 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-09-15 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-05 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-16 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-06-17 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2025-06-03 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-15 | Rob Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-04-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-21 | Bruce Westerman | Sale | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan | Sale | $15,001 - $50,000 |
| 2025-03-31 | Gilbert Cisneros | Sale (Full) | $15,001 - $50,000 |
| 2025-03-10 | Carol Devine Miller | Sale | $15,001 - $50,000 |
| 2025-03-10 | Carol Devine Miller | Sale (Full) | $1,001 - $15,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-26 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-02-25 | Rob Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-02-24 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-02-12 | Julie Johnson | Sale | $1,001 - $15,000 |
| 2025-01-24 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-01-15 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2024-11-26 | Michael Rulli | Sale | $1,001 - $15,000 |
| 2024-11-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-10-21 | Laurel Lee | Purchase | $15,001 - $50,000 |
| 2024-10-15 | Greg Landsman | Sale (Full) | $1,001 - $15,000 |
| 2024-08-09 | Kathy Manning | Sale (Full) | $1,001 - $15,000 |
| 2024-08-06 | Scott Mr Franklin | Sale (Full) | $15,001 - $50,000 |
| 2024-08-01 | Scott Mr Franklin | Sale (Full) | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-03-20 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-03-04 | Roger Williams | Sale (Full) | $1,001 - $15,000 |
| 2024-03-01 | Roger Williams | Sale (Full) | $1,001 - $15,000 |
| 2024-03-01 | Roger Williams | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-02-13 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2024-02-12 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2024-01-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-12-28 | Jared Moskowitz | Sale | $1,001 - $15,000 |
| 2023-12-12 | Kathy Manning | Sale | $1,001 - $15,000 |
| 2023-12-12 | Kathy Manning | Sale (Full) | $15,001 - $50,000 |
| 2023-11-28 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-24 | Greg Stanton | Sale | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-10-02 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-11 | Scott Mr Franklin | Sale (Full) | $15,001 - $50,000 |
| 2023-09-08 | Lois Frankel | Sale | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Purchase | $50,001 - $100,000 |
| 2023-09-01 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-07-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale | $15,001 - $50,000 |
| 2023-06-28 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-05-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-26 | Zoe Lofgren | Sale | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-04-28 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2023-04-25 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-04-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Sale | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-14 | Richard W. Allen | Sale (Full) | $15,001 - $50,000 |
| 2023-03-14 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-03-07 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2023-03-03 | Carol Devine Miller | Purchase | $1,001 - $15,000 |
| 2023-02-15 | Scott Mr Franklin | Sale | $15,001 - $50,000 |
| 2023-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-01 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-01-11 | Michael Patrick Guest | Sale (Full) | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-01-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-12 | Christopher L. Jacobs | Sale (Partial) | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-11-03 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-11-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-10-26 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-12 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2022-10-07 | Christopher L. Jacobs | Sale (Full) | $1,001 - $15,000 |
| 2021-07-15 | Richard W. Allen | Purchase | $15,001 - $50,000 |
Recent news
- 2026-08-17 Valneva: The Lyme Royalty Transition Changes The Earnings Model Valneva (VALN) is transitioning from a low-margin vaccine manufacturer to a high-margin royalty and milestone model, anchored by its Lyme disease partnership with Pfizer. Recent financials were impacted by IXCHIQ-related charges, but restructuring is improving the expense base and cash runway, with about three years of funding at current burn rates. Pfizer''s Lyme vaccine candidate, with 73% efficacy and EMA validation, positions VALN for significant royalty and milestone income if approved and successfully commercialized.
- 2026-08-17 Ballentine Partners LLC Sells 18,852 Shares of Pfizer Inc. $PFE Ballentine Partners LLC cut its holdings in Pfizer Inc. (NYSE: PFE) by 18.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,928 shares of the biopharmaceutical company''s stock after selling 18,852 shares during the quarter. Ballentine Partners LLC''s holdings in
- 2026-08-17 Elevated Capital Advisors LLC Lowers Stock Position in Pfizer Inc. $PFE Elevated Capital Advisors LLC cut its stake in shares of Pfizer Inc. (NYSE: PFE) by 53.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,185 shares of the biopharmaceutical company''s stock after selling 24,066 shares during the period.
- 2026-08-17 Burns Matteson Capital Management LLC Makes New $490,000 Investment in Pfizer Inc. $PFE Burns Matteson Capital Management LLC purchased a new stake in shares of Pfizer Inc. (NYSE: PFE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 20,337 shares of the biopharmaceutical company''s stock, valued at approximately $490,000. Other institutional investors have also recently
- 2026-08-14 Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase Three Pfizer insiders executed transactions directly on the heels of the drugmaker''s second-quarter earnings report.
- 2026-08-14 European Regulator Validates Pfizer and Valneva''s Lyme Disease Vaccine Application Valneva SE (NASDAQ:VALN) stock is surging on Friday after the company and its partner Pfizer Inc. (NYSE:PFE) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, their Lyme disease vaccine candidate.
- 2026-08-14 Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money Pharmaceutical company Pfizer has agreed to a $44 million class action settlement over its oral prescription medication Chantix. Approved by the FDA in May 2006 as a smoking-cessation aid, the drug was taken off the market in 2021.
- 2026-08-14 3 High-Yield Dividend Stocks Under $30 to Buy in August Three dividend stocks near or under $30 caught our attention this August, and at least one of them carries a yield so high it comes with a built-in warning label worth reading before you buy.
- 2026-08-14 Pfizer and Valneva''s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing
- 2026-08-14 Pfizer and Valneva''s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies'' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.